BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 16344723)

  • 1. Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations.
    Schirmer M; Toliat MR; Haberl M; Suk A; Kamdem LK; Klein K; Brockmöller J; Nürnberg P; Zanger UM; Wojnowski L
    Pharmacogenet Genomics; 2006 Jan; 16(1):59-71. PubMed ID: 16344723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic contribution to variable human CYP3A-mediated metabolism.
    Lamba JK; Lin YS; Schuetz EG; Thummel KE
    Adv Drug Deliv Rev; 2002 Nov; 54(10):1271-94. PubMed ID: 12406645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP3A4 and CYP3A5 genotyping by Pyrosequencing.
    Garsa AA; McLeod HL; Marsh S
    BMC Med Genet; 2005 May; 6():19. PubMed ID: 15882469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism.
    Wandel C; Witte JS; Hall JM; Stein CM; Wood AJ; Wilkinson GR
    Clin Pharmacol Ther; 2000 Jul; 68(1):82-91. PubMed ID: 10945319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Similarity in recombination rate and linkage disequilibrium at CYP2C and CYP2D cytochrome P450 gene regions among Europeans indicates signs of selection and no advantage of using tagSNPs in population isolates.
    Pimenoff VN; Laval G; Comas D; Palo JU; Gut I; Cann H; Excoffier L; Sajantila A
    Pharmacogenet Genomics; 2012 Dec; 22(12):846-57. PubMed ID: 23089684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity.
    Sata F; Sapone A; Elizondo G; Stocker P; Miller VP; Zheng W; Raunio H; Crespi CL; Gonzalez FJ
    Clin Pharmacol Ther; 2000 Jan; 67(1):48-56. PubMed ID: 10668853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4.
    Zeigler-Johnson CM; Walker AH; Mancke B; Spangler E; Jalloh M; McBride S; Deitz A; Malkowicz SB; Ofori-Adjei D; Gueye SM; Rebbeck TR
    Hum Hered; 2002; 54(1):13-21. PubMed ID: 12446983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequence diversity and haplotype structure at the human CYP3A cluster.
    Thompson EE; Kuttab-Boulos H; Yang L; Roe BA; Di Rienzo A
    Pharmacogenomics J; 2006; 6(2):105-14. PubMed ID: 16314882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online.
    Walker AH; Jaffe JM; Gunasegaram S; Cummings SA; Huang CS; Chern HD; Olopade OI; Weber BL; Rebbeck TR
    Hum Mutat; 1998; 12(4):289. PubMed ID: 10660343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between Spaniards and Other Caucasian populations.
    Gervasini G; Vizcaino S; Gasiba C; Carrillo JA; Benitez J
    Ther Drug Monit; 2005 Dec; 27(6):819-21. PubMed ID: 16306861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of genotypes of the CYP3A cluster with midazolam disposition in vivo.
    Miao J; Jin Y; Marunde RL; Gorski CJ; Kim S; Quinney S; Radovich M; Li L; Hall SD
    Pharmacogenomics J; 2009 Oct; 9(5):319-26. PubMed ID: 19506580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population.
    Du J; Xing Q; Xu L; Xu M; Shu A; Shi Y; Yu L; Zhang A; Wang L; Wang H; Li X; Feng G; He L
    Pharmacogenomics; 2006 Sep; 7(6):831-41. PubMed ID: 16981844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening CYP3A single nucleotide polymorphisms in a Han Chinese population with a genotyping chip.
    Liu CH; Peck K; Huang JD; Lin MS; Wang CH; Hsu WP; Wang HW; Lee HL; Lai ML
    Pharmacogenomics; 2005 Oct; 6(7):731-47. PubMed ID: 16207150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose.
    Dally H; Edler L; Jäger B; Schmezer P; Spiegelhalder B; Dienemann H; Drings P; Schulz V; Kayser K; Bartsch H; Risch A
    Pharmacogenetics; 2003 Oct; 13(10):607-18. PubMed ID: 14515059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of linkage disequilibrium patterns and haplotype structure of eight single nucleotide polymorphisms across the CYP1A2 gene between the Korean, and other populations registered in the International HapMap database.
    Woo SW; Kang TS; Park HJ; Lee JE; Roh J
    J Clin Pharm Ther; 2009 Aug; 34(4):429-36. PubMed ID: 19583676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of genetic variation in the hypertension candidate gene GRK4: ethnic variation and haplotype structure.
    Lohmueller KE; Wong LJ; Mauney MM; Jiang L; Felder RA; Jose PA; Williams SM
    Ann Hum Genet; 2006 Jan; 70(Pt 1):27-41. PubMed ID: 16441255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP3A5*3 and CYP3A4*1B allele distribution and genotype combinations: differences between Spaniards and Central Americans.
    Sinues B; Vicente J; Fanlo A; Vasquez P; Medina JC; Mayayo E; Conde B; Arenaz I; Martinez-Jarreta B
    Ther Drug Monit; 2007 Aug; 29(4):412-6. PubMed ID: 17667794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles.
    Rodríguez-Antona C; Sayi JG; Gustafsson LL; Bertilsson L; Ingelman-Sundberg M
    Biochem Biophys Res Commun; 2005 Dec; 338(1):299-305. PubMed ID: 16171783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype.
    Lee SJ; Bell DA; Coulter SJ; Ghanayem B; Goldstein JA
    J Pharmacol Exp Ther; 2005 Apr; 313(1):302-9. PubMed ID: 15634941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos.
    Dai D; Tang J; Rose R; Hodgson E; Bienstock RJ; Mohrenweiser HW; Goldstein JA
    J Pharmacol Exp Ther; 2001 Dec; 299(3):825-31. PubMed ID: 11714865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.